Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
Drug trials are divided into four phases, though a drug only has to successfully negotiate three of these four stages to receive sign-off by the regulatory bodies
The act of securing of licensing deals and partnerships is such an important value inflexion point for smaller drug developers, it warrants a more detailed write up of its own
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
Clevegen has shown no toxicologically relevant changes in any subject in dose escalation studies.
The company specialises in games for mobile devices. It's focus is on an under-served market, women over the age of 30
The company makes specialist equipment for the life sciences, healthcare, astronomy, consumer manufacturing and art conservation markets
It will receive an initial US$200mln followed by a further US$10mln, plus sales-related milestone payments
The company is now fully funded to implement its new business plan